The estimated Net Worth of Lawrence P. Wennogle is at least 10.8 百万$ dollars as of 8 June 2015. Lawrence Wennogle owns over 25,000 units of Intra-Cellular Therapies Inc stock worth over 9,452,080$ and over the last 11 years Lawrence sold ITCI stock worth over 1,361,000$.
Sign up
Lawrence Wennogle ITCI stock SEC Form 4 insiders trading
Lawrence has made over 10 trades of the Intra-Cellular Therapies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Lawrence sold 25,000 units of ITCI stock worth 671,000$ on 8 June 2015.
The largest trade Lawrence's ever made was exercising 47,500 units of Intra-Cellular Therapies Inc stock on 19 May 2015 worth over 58,425$. On average, Lawrence trades about 13,000 units every 32 days since 2014. As of 8 June 2015 Lawrence still owns at least 126,500 units of Intra-Cellular Therapies Inc stock.
You can see the complete history of Lawrence Wennogle stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Lawrence Wennogle's mailing address?
Lawrence's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK, NY, 10032.
Insiders trading at Intra-Cellular Therapies Inc
Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over 77,703,646$ worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth 52,322,638$ . The most active insiders traders include Rory B Riggs、Joel S Marcus、Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of 2,787,280$. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth 891,100$.
What does Intra-Cellular Therapies Inc do?
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
What does Intra-Cellular Therapies Inc's logo look like?
Complete history of Lawrence Wennogle stock trades at Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc executives and stock owners
Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:
-
Sharon Mates,
Chairman of the Board, President, Chief Executive Officer -
Mark Neumann,
Executive Vice President, Chief Commercial Officer -
Michael Halstead,
Executive Vice President, General Counsel and Secretary -
Lawrence Hineline,
Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary -
Robert Davis,
Senior Vice President and Chief Scientific Officer -
Kimberly Vanover,
Senior Vice President, Early Stage Clinical Development and Translational Medicines -
Dr. Sharon Mates,
Co-Founder, Chairman, CEO & Pres -
Mark Neumann,
EVP & Chief Commercial Officer -
Michael I. Halstead J.D.,
Exec. VP, Gen. Counsel & Sec. -
Dr. Suresh K. Durgam M.D.,
Sr. VP & Chief Medical Officer -
Lawrence J. Hineline CPA, CPA,
Sr. VP of Fin., CFO, Treasurer & Assistant Sec. -
Robert Van Nostrand,
Lead Independent Director -
Joel Marcus,
Independent Director -
Christopher Alafi,
Independent Director -
Rory Riggs,
Independent Director -
Richard Lerner,
Independent Director -
Michael Olchaskey,
Senior Vice President, Head of Regulatory Affairs -
Suresh Durgam,
Chief Medical Officer -
John Bardi,
Senior Vice President - Market Access, Policy and Government Affairs -
Karen Patruno Sheehy Esq.,
Sr. VP & Chief Compliance Officer -
Juan Fernando Sanchez,
VP of Corp. Communications & Investor Relations -
Dr. Robert E. Davis Ph.D.,
Sr. VP & Chief Scientific Officer -
Moshe Alafi,
10% owner -
Capital Co Llc Alafi,
10% owner -
Juan F. Sanchez,
VP, Corp. Communications & IR -
Allen A. Fienberg,
VP of Business Development -
Lawrence P. Wennogle,
Vice President, Drug Discovery -
Michael Rawlins,
Director -
Eduardo Rene Salas,
-
Sanjeev Narula,
Executive Vice President & CFO